22157.jpg
Insights on the Genetic Testing for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions Global Market to 2025
15 févr. 2021 05h43 HE | Research and Markets
Dublin, Feb. 15, 2021 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets for Epilepsy, Autism, Alzheimer's and Other Neurologic Conditions" report has been added to ResearchAndMarkets.com's offering. ...
brsf.png
Brain Scientific, Creator of Next Gen Neurology Technologies, Announces Regulation A+ Offering
15 déc. 2020 08h30 HE | Brain Scientific Inc.
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Brain Scientific Inc. (OTCQB: BRSF), a neurology-focused medical device and software company, today announced it has launched a...
Screenshot 2018-10-08 at 5.23.34 PM.png
Karamedica Announces National Institute on Aging Grant to Continue Development of Microparticle Therapy for Cerebral Amyloid Angiopathy
15 déc. 2020 07h55 HE | Karamedica, Inc.
RALEIGH, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Karamedica, Inc. recently received a $2.5 million Small Business Innovative Research (SBIR) Phase II grant from the National Institute on Aging to...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Awarded $15 Million Grant from National Institute on Aging to Support ACT-AD Clinical Trial in Alzheimer’s Disease
08 déc. 2020 07h30 HE | Athira Pharma, Inc.
SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Initiation of Patient Dosing for ACT-AD Clinical Trial of ATH-1017, Small Molecule HGF/MET Activator, for Treatment of Mild-to-Moderate Alzheimer’s Disease
01 déc. 2020 07h30 HE | Athira Pharma, Inc.
SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
When a wife struggles alone as a caretaker of her husband with Alzheimer’s, she realized the need for help from people around her
10 nov. 2020 01h13 HE | Balboa Press
PHOENIX, Nov. 10, 2020 (GLOBE NEWSWIRE) -- “I journeyed with dementia as I care for my own mother and husband. I want people to gain a sense of hope that there is light at the end of caring for...
Alzamend Neuro - Corporate Logo Bar and Head w TM Only 01032017.jpg
New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
27 oct. 2020 06h56 HE | Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
DPW Holdings - Corporate Logo Dark Blue Lettering Only 01052018 Web.png
DPW Holdings’ Announces that the Journal of Alzheimer’s Disease Highlights Milestone Research (AL002) Licensed by Alzamend Neuro® from the University of South Florida
27 oct. 2020 06h30 HE | Alzamend Neuro, Inc.
NEWPORT BEACH, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- DPW Holdings, Inc. (NYSE American: DPW) a diversified holding company (“DPW,” or the “Company”) announced that the Journal of Alzheimer’s...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma to Host Educational Webinar on the Predictive Nature of P300 to Determine Clinical Benefit of Alzheimer’s Disease Treatments
21 oct. 2020 07h30 HE | Athira Pharma, Inc.
- Expert neuropsychiatric clinician to discuss the testing method and its correlation to clinical results - Event to feature an in-clinic demonstration of P300 testing - Webcast to be held on...
Annovis_Corp_Image.png
Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
15 oct. 2020 06h45 HE | Annovis Bio Inc.
BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...